Overview of Resonate-2 clinical trial of ibrutinib in CLL

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the use of ibrutinib as front-line therapy in chronic lymphocytic leukemia (CLL).